DarioHealth Corp. (DRIO)

From the record

DarioHealth Corp.'s filings since 2017 show 5 warning events of 3 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2023-02-06); a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2025-03-19); a warning not to rely on past financial statements (8-K item 4.02, the latest 2018-03-19) (its current reports).

From the record

DarioHealth Corp.'s 8 filed years say what it did: revenue went from $7 million in fiscal 2018 to $22 million in fiscal 2025, up 17.1% a year; it rose in 5 of 7 years; the deepest fall was 26% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 8 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, DarioHealth Corp. lost about 61 cents for every dollar of shareholders' money, and gross profitability: its products earned about 12 cents per dollar of everything the company owns. Leverage: it owed about 38 cents per dollar of assets, and net share issuance: its share count grew 62.4% over the year (the filed statements).

From the record

DarioHealth Corp.'s standing among 109 graded names in its industry family: revenue of $22 million in fiscal 2025 ranks in the bottom 29% by size; a net margin of -186.6% ranks in the bottom 20%; revenue growth of -6.8% a year over the last 3 filed years ranks in the bottom 16% (its annual reports).

From the record

DarioHealth Corp.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Raphael, Erez (Chief Executive Officer, as filed), filing under that title since 2016-03-03, 10.7 years (top 19% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 6.3 years (top 34%); 13 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 13%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

DarioHealth Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $22 million against debt of $31 million leaves -8.1% of its assets as net cash, bottom 29% of its family; cash from operations less capital spending is -116.7% of revenue (bottom 20%); a gross margin of 56.6% (bottom 44%); research spending of 61.7% of revenue (top 18%) (its annual report).

From the record

DarioHealth Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew -6.8% a year over the last three filed years against 17.1% over all 8, slowing (bottom 10% of its family); the newest year grew -17.3% (bottom 10%); research spending grew -11.1% a year (bottom 15%); capital spending grew -31.5% a year (bottom 16%) (its annual reports). DarioHealth Corp. reported 2 product lines in fiscal 2025: Service at $15 million (67%), Hardware and Consumable Products at $7 million (33%); 1 of 2 grew against the year before (its annual report).

From the record

DarioHealth Corp.'s newest year against its own record: revenue of $22 million in fiscal 2025 came in 16.4% below the $27 million its prior three years' pace pointed to (bottom 25% of its family); net income of $42 million against a prior three-year average of $55 million (top 45%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 22%) (its annual reports).